Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 2Colorectal Neoplasms 2Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Colonic Neoplasms 1

Interventions

Irinotecan 30Gemcitabine 25Paclitaxel 24Cisplatin 24Docetaxel 19Oxaliplatin 15Fluorouracil 15alvocidib 13Leucovorin 13Carboplatin 12Capecitabine 12Bortezomib 10Taxes 83-aminopyridine-2-carboxaldehyde thiosemicarbazone 7ixabepilone 6Vorinostat 6Topotecan 6Temozolomide 6Immunohistochemistry 6Immunoenzyme Techniques 6Bevacizumab 67-hydroxystaurosporine 6tanespimycin 5Sorafenib 5Pharmacogenomic Testing 5Pemetrexed 5Etoposide 5Chromatography, High Pressure Liquid 57-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine 5temsirolimus 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Unspecified Adult Solid Tumor, Protocol Specific × raltitrexed × Clear all
NCT00002902 2019-03-13

Irinotecan Plus ICI D1694 in Treating Patients With Advanced Solid Tumors

Abramson Cancer Center at Penn Medicine

Phase 1 Completed
Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

NCT00003109 2013-04-17

Irinotecan Plus Raltitrexed in Treating Patients With Refractory Solid Tumors

Fox Chase Cancer Center

Phase 1 Completed
39 enrolled
Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

Data powered by HemOnc (CC BY 4.0) Colophon âš¡